Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model.

Muls, E; Van Ganse, E; Closon, M C

Muls, E; Van Ganse, E; Closon, M C.

Affiliation

Muls E; Department of Endocrinology, Metabolism and Nutrition, UZ Gathuisberg, Katholieke Universiteit Leuven, Belgium.

Atherosclerosis ; 137 Suppl: S111-6, 1998 Apr.

Article in En | MEDLINE | ID: mdl-9694550

Subject(s)

Anticholesteremic Agents/economics; Anticholesteremic Agents/therapeutic use; Coronary Disease/prevention & control; Pravastatin/economics; Pravastatin/therapeutic use; Belgium; Cost-Benefit Analysis; Double-Blind Method; Female; Forecasting; Humans; Life Expectancy; Male; Middle Aged; Models, Economic; Risk Factors; Sensitivity and Specificity; United States

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pravastatin / Coronary Disease / Anticholesteremic Agents Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Country/Region as subject: America do norte / Europa Language: En Journal: Atherosclerosis Year: 1998 Type: Article Affiliation country: Belgium

Search on Google

XML

PubMed Links